Menu Back to Global-Forum-for-Qualified-Persons-for-Pharmacovigilance-QPPV

Overview

In a changing and expanding world, this is still the only forum designed for QPPVs by QPPVs, now in its 15th year and still going strong.

2021 Focus: The Evolution of QPPV

The QPPV Forum focuses on international QPs’ role and gives a high-level approach to the discussed topics and continues to identify key trends requiring QPPV awareness, input and oversight. This year’s objectives are built on past successes and have been shaped by valuable feedback provided by participants of the past fourteen meetings, plus many years of QPPV and Regulator interaction at this Forum. Moreover, we are looking forward to receiving information and discuss pragmatic approaches on the modern technology and how this will impact the QPPV Role.


Featured Topics

  • The Role of QPPV: Evolution and Future Challenges/Expectations
  • Learnings from COVID-19 Pandemic: QPPV Role and Involvement
  • QPPV Requirements and Expectations in Non-EU Countries
  • QPPV Oversight: Interaction between QPPV and local QPPVs, Non-EU QPPV
  • UK Pharmacovigilance Requirements Post-EU Exit: Where are we now?”
  • QPPV Talks

Learning Objectives

  • Hear the latest updates and hot topics relating to the role of the QPPV
  • Explore long term PV visions, future directions of the ‘PV world’, and potential impact on the role of the QPPV
  • Network with colleagues and meet regulators
  • Learn from and share experience and ideas with like-minded QPPVs in a neutral environment
  • Better understand regulatory and inspectorate expectations globally
  • Examine current challenges and share potential solutions

90 percent of previous participants found the forum relevant for their work. Here is why: 

“A great platform of learning and exchanging the knowledge. All speakers of DIA trainings are highly experienced and they share their practical experiences which makes this event excellent. Thank you.” Phanindra Singh, 4C Pharma Solutions


An Event Designed With the QPPV Community


Who should attend?

  • Global QPPVs/ Deputies
  • Regulators
  • Pharmacovigilance Consultants
  • Directors of Pharmacovigilance Oversight and Standards
  • Drug Safety Managers/Leaders
  • Auditors
  • Medical and Regulatory Affairs Experts
  • Aspiring PV Specialists/QPPVs

Program Committee

  • Willemijn  van der Spuij, MSc
    Willemijn van der Spuij, MSc Executive Director, WorldWide Patient Safety International, Europe
    Bristol-Myers Squibb, Switzerland
  • Angela  Van Der Salm, DrSc, PhD
    Angela Van Der Salm, DrSc, PhD Director Pharmacovigilance
    DADA Consultancy, Netherlands
  • Shahinaz  Badr
    Shahinaz Badr Regional Pharmacovigilance Manager - Africa, Middle East and Turkey
    Newbridge Pharmaceuticals, United Arab Emirates
  • Vicki  Edwards GBh
    Vicki Edwards GBh Vice President, Pharmacovigilance Excellence and International QPPV
    AbbVie, Inc., United Kingdom
  • Gemma  Jimenez Sese
    Gemma Jimenez Sese CORPORATE DRUG SAFETY HEAD - EUQPPV
    ALMIRALL, S.A., Spain
  • Maarten  Lagendijk, MSc
    Maarten Lagendijk, MSc Deputy EU QPPV
    MSD, Netherlands
  • Elspeth  McIntosh
    Elspeth McIntosh Director
    Castle Pharmacovigilance Limited, United Kingdom
  • Doris Irene Stenver, MD, MPA
    Doris Irene Stenver, MD, MPA Independent Pharmacovigilance Adviser
    Unique Advice, Denmark
  • Katarzyna  Swiderek, MPharm, RPh
    Katarzyna Swiderek, MPharm, RPh Manager, Safety Evaluation Risk Management (SERM)
    GlaxoSmithKline, Poland
  • Kiernan  Trevett, MSc
    Kiernan Trevett, MSc Expert Pharmacovigilance Inspector
    Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
  • Nicolas  Tsiakkas, MD
    Nicolas Tsiakkas, MD Scientific Director
    Nicolas Tsiakkas & Co OE VAT Nr EL099974907, Greece
  • Anja  Van Haren, MSc
    Anja Van Haren, MSc EudraVigilance Coordinator
    Medicines Evaluation Board (MEB), Netherlands
  • Magnus  Ysander, MD
    Magnus Ysander, MD EU QPPV & Head Pharmacovigilance Excellence
    AstraZeneca, Sweden
Load More